Compare RECT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RECT | SKYE |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 44.9M |
| IPO Year | 2024 | N/A |
| Metric | RECT | SKYE |
|---|---|---|
| Price | $1.81 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 11.2K | ★ 260.6K |
| Earning Date | 07-31-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $32,594,177.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.61 | ★ N/A |
| Revenue Growth | ★ 5.91 | N/A |
| 52 Week Low | $1.79 | $1.09 |
| 52 Week High | $7.68 | $5.75 |
| Indicator | RECT | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 27.15 | 34.16 |
| Support Level | $1.79 | $1.10 |
| Resistance Level | $2.12 | $1.27 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 9.09 | 13.24 |
Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks. Additionally the company has added auxiliary products such as industrial hardware tools and electrical hardware required for construction sites.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.